BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $415

Benzinga Newsdesk www.benzinga.com Negative 44.7%

Neg 44.7% Neu 0% Pos 0%

BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Market Perform and lowers the price target from $450 to $415.